Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.

Wang S, Zhou Q, Gallo JM.

Mol Cancer Ther. 2009 Jun;8(6):1438-47. doi: 10.1158/1535-7163.MCT-09-0089. Epub 2009 Jun 9.

PMID:
19509243
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM.

Mol Cancer Ther. 2008 Feb;7(2):407-17. doi: 10.1158/1535-7163.MCT-07-2070.

PMID:
18281523
[PubMed - indexed for MEDLINE]
Free Article
3.

Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.

Sharma J, Lv H, Gallo JM.

Cancer Res. 2013 Aug 15;73(16):5242-52. doi: 10.1158/0008-5472.CAN-13-0690. Epub 2013 Jun 24.

PMID:
23796561
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.

Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY.

Cancer Chemother Pharmacol. 2005 Nov;56(5):455-64. Epub 2005 Jun 10.

PMID:
15947929
[PubMed - indexed for MEDLINE]
5.

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.

Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J.

Clin Cancer Res. 2012 Jun 1;18(11):3090-9. doi: 10.1158/1078-0432.CCR-12-0445. Epub 2012 Apr 10.

PMID:
22496205
[PubMed - indexed for MEDLINE]
Free Article
6.

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.

Clin Cancer Res. 2006 Jan 15;12(2):617-25.

PMID:
16428508
[PubMed - indexed for MEDLINE]
Free Article
7.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2004 May 1;10(9):3216-24.

PMID:
15131063
[PubMed - indexed for MEDLINE]
Free Article
8.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC.

Mol Cancer Ther. 2005 Apr;4(4):641-9.

PMID:
15827338
[PubMed - indexed for MEDLINE]
Free Article
9.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
10.

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.

Hayakawa H, Ichihara E, Ohashi K, Ninomiya T, Yasugi M, Takata S, Sakai K, Matsumoto K, Takigawa N, Tanimoto M, Kiura K.

Cancer Sci. 2013 Nov;104(11):1440-6. doi: 10.1111/cas.12284. Epub 2013 Oct 25.

PMID:
24033722
[PubMed - indexed for MEDLINE]
11.

Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.

Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR.

Clin Cancer Res. 2004 Jul 15;10(14):4874-84.

PMID:
15269164
[PubMed - indexed for MEDLINE]
Free Article
13.

Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.

Wu Q, Li MY, Li HQ, Deng CH, Li L, Zhou TY, Lu W.

Acta Pharmacol Sin. 2013 Nov;34(11):1427-36. doi: 10.1038/aps.2013.101. Epub 2013 Oct 7.

PMID:
24096601
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.

Zhao S, Kuge Y, Zhao Y, Takeuchi S, Hirata K, Takei T, Shiga T, Dosaka-Akita H, Tamaki N.

BMC Cancer. 2013 Nov 6;13:525. doi: 10.1186/1471-2407-13-525.

PMID:
24191959
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

PMID:
21858220
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.

Sharma J, Lv H, Gallo JM.

J Pharm Sci. 2012 Nov;101(11):4100-6. doi: 10.1002/jps.23283. Epub 2012 Aug 1.

PMID:
22865095
[PubMed - indexed for MEDLINE]
17.

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.

Clin Cancer Res. 2004 Jul 15;10(14):4858-64.

PMID:
15269162
[PubMed - indexed for MEDLINE]
Free Article
18.

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S.

Mol Cancer Ther. 2006 Jul;5(7):1895-903.

PMID:
16891476
[PubMed - indexed for MEDLINE]
Free Article
19.

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M.

Xenobiotica. 2006 Jan;36(1):29-39.

PMID:
16507511
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.

Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE.

Clin Cancer Res. 2011 Jul 15;17(14):4682-92. doi: 10.1158/1078-0432.CCR-11-0975. Epub 2011 May 24.

PMID:
21610148
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk